VYNE - VYNE Therapeutics Inc
IEX Last Trade
1.835
0.025 1.362%
Share volume: 20,012
Last Updated: Fri 30 Aug 2024 09:59:19 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.81
0.03
1.38%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-14 | 2023-03-14 | 2023-05-11 | 2023-08-14 | 2023-11-13 | 2024-03-01 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 55.192 M | 46.908 M | 40.758 M | 35.263 M | 24.959 M | 19.267 M | 97.685 M | 91.676 M | |
| Current Assets | 51.920 M | 44.046 M | 38.275 M | 33.022 M | 22.959 M | 17.511 M | 95.963 M | 90.223 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 8.802 M | 7.998 M | 7.127 M | 2.637 M | 2.024 M | 1.759 M | 2.656 M | 4.219 M | |
| Short Term Investments | 8.802 M | 7.998 M | 7.127 M | 2.637 M | 2.024 M | 1.759 M | 2.656 M | 4.219 M | |
| Total Receivables | 304.000 K | 471.000 K | 173.000 K | 105.000 K | 234.000 K | 250.000 K | 0.000 | 0.000 | |
| Current Cash | 42.814 M | 35.510 M | 30.908 M | 30.213 M | 20.634 M | 15.448 M | 93.253 M | 85.950 M | |
| Total Non-current Assets | 3.272 M | 2.862 M | 2.483 M | 2.241 M | 2.000 M | 1.756 M | 1.722 M | 1.453 M | |
| Property Plant Equipment | 298.000 K | 127.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 2.974 M | 2.735 M | 2.483 M | 2.241 M | 2.000 M | 1.756 M | 1.722 M | 1.453 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 55.192 M | 46.908 M | 40.758 M | 35.263 M | 24.959 M | 19.267 M | 97.685 M | 91.676 M | |
| Total liabilities | 6.835 M | 6.839 M | 9.556 M | 8.832 M | 7.687 M | 7.762 M | 8.950 M | 8.306 M | |
| Total current liabilities | 6.835 M | 6.839 M | 9.345 M | 7.519 M | 6.374 M | 6.449 M | 7.538 M | 6.930 M | |
| Accounts Payable | 1.431 M | 2.523 M | 2.386 M | 2.214 M | 1.159 M | 716.000 K | 1.659 M | 2.795 M | |
| Other liabilities | 0.000 | 0.000 | 211.000 K | 1.313 M | 1.313 M | 1.313 M | 1.313 M | 1.313 M | |
| Current long term debt | 31.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 115.000 K | 117.000 K | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 99.000 K | 63.000 K | |
| Other liabilities | 0.000 | 0.000 | 211.000 K | 1.313 M | 1.313 M | 1.313 M | 1.313 M | 1.313 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 48.357 M | 40.069 M | 31.202 M | 26.431 M | 17.272 M | 11.505 M | 88.735 M | 83.370 M | |
| Common stock | 3.218 M | 3.218 M | 3.230 M | 3.255 M | 3.274 M | 3.282 M | 31.281 M | 42.581 M | |
| Retained earnings | -643.331 M | -652.790 M | -662.735 M | -668.506 M | -678.564 M | -685.148 M | -691.336 M | -697.585 M |